The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci

Diagnostic Microbiology and Infectious Disease

Volumn 56, Issue 4, 2006, Pages 407-413

  Scheetz, Marc H ^a   Qi, Chao ^a   Noskin, Gary A ^b   Warren, John R ^a   Postelnick, Michael J ^a   Malczynski, Michael ^a   Huang, Jie ^b   Zembower, Teresa R ^b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antimicrobial resistance; Linezolid; Susceptibility testing; Vancomycin resistant enterococci

Indexed keywords

AMPICILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; PIPERACILLIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SENSITIVITY; ENTEROCOCCAL INFECTION; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SURGICAL TECHNIQUE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACADEMIC MEDICAL CENTERS; ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; COHORT STUDIES; CROSS INFECTION; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 33845288401     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.06.018     Document Type: Article

References (26)

1. Biedenbach D.J., Moet G.J., and Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50 (2004) 59-69
2. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36 (2003) 159-168
3. Brauers J., Kresken M., Hafner D., and Shah P.M. Surveillance of linezolid resistance in Germany, 2001-2002. Clin. Microbiol. Infect. 11 (2005) 39-46
4. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 40 (1987) 373-383
5. Clinical and Laboratory Standards Institute/NCCLS. Performance standards for antimicrobial susceptibility testing; Fifteenth Informational Supplement. CLSI/NCCLS document M100-S15 (2005), Clinical and Laboratory Standards Institute, Wayne, PA. 1-56238-556-9
6. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45 (1992) 613-619
7. Facklam R., and Elliott J.A. Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Clin. Microbiol. Rev. 8 (1995) 479-495
8. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16 (1988) 128-140
9. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
10. Hurley J.C. Mortality due to vancomycin-resistant enterococcal bacteremia versus vancomycin-susceptible enterococcal bacteremia: an ecological analysis. Clin. Infect. Dis. 41 (2005) 1541-1542
11. Linden P.K., Moellering Jr. R.C., Wood C.A., Rehm S.J., Flaherty J., Bompart F., and Talbot G.H. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin. Infect. Dis. 33 (2001) 1816-1823
12. Marshall S.H., Donskey C.J., Hutton-Thomas R., Salata R.A., and Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46 (2002) 3334-3336
13. Meka V.G., and Gold H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39 (2004) 1010-1015
14. Murray B.E. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342 (2000) 710-721
15. Mutnick A.H., Enne V., and Jones R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37 (2003) 769-774
16. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32 (2004) 470-485
17. Pai M.P., Rodvold K.A., Schreckenberger P.C., Gonzales R.D., Petrolatti J.M., and Quinn J.P. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 35 (2002) 1269-1272
18. Prystowsky J., Siddiqui F., Chosay J., Shinabarger D.L., Millichap J., Peterson L.R., and Noskin G.A. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45 (2001) 2154-2156
19. Qi C., Zheng X., Obias A., Scheetz M.H., Malczynski M., and Warren J.R. Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis. J. Clin. Microbiol. 44 (2006) 1098-1100
20. Raad I.I., Hanna H.A., Hachem R.Y., Dvorak T., Arbuckle R.B., Chaiban G., and Rice L.B. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob. Agents Chemother. 48 (2004) 3583-3585
21. Ruggero K.A., Schroeder L.K., Schreckenberger P.C., Mankin A.S., and Quinn J.P. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn. Microbiol. Infect. Dis. 47 (2003) 511-513
22. Sinclair A., Arnold C., and Woodford N. Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in enterococci. Antimicrob. Agents Chemother. 47 (2003) 3620-3622
23. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., and Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33 (1995) 2233-2239
24. Turabelidze D., Kotetishvili M., Kreger A., Morris Jr. J.G., and Sulakvelidze A. Improved pulsed-field gel electrophoresis for typing vancomycin-resistant enterococci. J. Clin. Microbiol. 38 (2000) 4242-4245
25. Werner G., Strommenger B., Klare I., and Witte W. Molecular detection of linezolid resistance in Enterococcus faecium and Enterococcus faecalis by use of 5' nuclease real-time PCR compared to a modified classical approach. J. Clin. Microbiol. 42 (2004) 5327-5331
26. Woodford N., Tysall L., Auckland C., Stockdale M.W., Lawson A.J., Walker R.A., and Livermore D.M. Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis. J. Clin. Microbiol. 40 (2002) 4298-4300